Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	6 Months Ended
	Mar. 31, 2012	Mar. 31, 2011
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (12,075,172)	$ (20,280,556)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	281,853	286,288
Issuance of common stock, warrants and options for services	243,708	132,946
Modification of stock options and warrants	36,990	135,988
Employee option cost	1,261,060	697,464
Common stock contributed to 401(k) plan	75,889	71,090
Impairment loss on abandonment of patents	21,334	0
Loss on retired equipment	4,065	237
Gain/loss on derivative instruments	3,247,857	(1,115,692)
Change in assets and liabilities:
Decrease (increase) in receivables	355,879	(169,397)
Decrease in deferred rent	301,837	308,065
Decrease (increase) in prepaid expenses	376,182	(2,054,195)
Decrease in inventory used for R&D and manufacturing	202,778	2,214
Decrease in accounts payable	(30,862)	(607,059)
(Decrease)/increase in accrued expenses	(99,019)	12,027,668
Decrease in due to employees	(369)	18,201
Deferred rent liability	(2,759)	(1,460)
Increase in deferred revenue	1,500	0
Increase in deposits held	5,000	0
NET CASH USED IN OPERATING ACTIVITIES	(5,792,249)	(10,548,198)
CASH FLOWS FROM INVESTING ACTIVITIES:
Decrease in restricted cash	0	21,357
Purchases of equipment	(30,810)	(96,588)
Expenditures for Patent costs	(50,480)	(39,431)
NET CASH USED IN INVESTING ACTIVITIES	(81,290)	(114,662)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock	9,166,800	1,406,368
Proceeds from exercise of warrants and stock options	2,664,539	429,588
Payments on convertible debt	(4,950,000)	0
NET CASH PROVIDED BY FINANCING ACTIVITIES	6,881,339	1,835,956
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	1,007,800	(8,826,904)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	4,260,594	26,568,243
CASH AND CASH EQUIVALENTS, END OF PERIOD	5,268,394	17,741,339
Issuance of warrants:
Increase in derivative liabilities	(4,546,667)	0
Decrease in additional paid-in capital	4,546,667	0
Total	0	0
Issuance of additional shares:
Increase in common stock	(8,333)	0
Increase in additional paid-in capital	(241,667)	0
Decrease in additional paid-in capital	250,000	0
Total	0	0
Exercise of derivative liabilities:
Decrease in derivative liabilities	122,367	202,830
Increase in additional paid-in capital	(122,367)	(202,830)
Total	0	0
Modification of warrants:
Increase in additional paid-in capital	(325,620)	(1,068,369)
Decrease in additional paid-in capital	325,620	1,068,369
Total	0	0
INDUCEMENT WARRANTS:
Increase in additional paid-in capital	(1,593,000)	0
Decrease in additional paid-in capital	1,593,000	0
Total	0	0
ISSUANCE OF COMMON STOCK FOR PREPAID SERVICES:
Increase in additional paid-in capital	(213,333)	0
Increase in prepaid expenses	213,333	0
Total	0	0
Patent costs included in accounts payable:
Increase in patent costs	0	34,635
Increase in accounts payable	0	(34,635)
Total	0	0
Equipment costs included in accounts payable:
Increase in research and office equipment	0	16,641
Increase in accounts payable for Equipment costs	0	(16,641)
Total	0	0
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Cash expenditures for interest expense	$ 294,910	$ 82,804